Transitional Cell Carcinoma Completed Phase 2 Trials for Enfortumab vedotin (DB13007)

Also known as: Carcinoma, Transitional Cell / Carcinoma transitional cell / Transitional cell carcinoma (morphologic abnormality)

IndicationStatusPhase
DBCOND0031000 (Transitional Cell Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03219333A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder CancerTreatment